Institute for Ageing and Health, UK NIHR Biomedical Research Centre in Ageing and Age-related Diseases-Cardiovascular theme & Falls and Syncope Service, Newcastle University, Newcastle, UK.
Europace. 2011 Mar;13(3):427-30. doi: 10.1093/europace/euq390. Epub 2010 Nov 9.
Postural orthostatic tachycardia syndrome (POTS) is associated with tachycardia on orthostasis. Patients frequently report palpitations, presyncope, and fatigue. Conventional therapy is effective in less than 60%. Case reports suggest ivabradine (a selective sinus node blocker, with no effect on blood pressure) may alleviate POTS-related symptoms. This is a retrospective case-series.
Postural orthostatic tachycardia syndrome patients prescribed ivabradine were identified from the pharmacy database. Case notes were reviewed and participants completed a symptom assessment tool. Twenty-two patients were identified. Data were available from 20. Eight patients reported reduced tachycardia and fatigue and four reported only reduced tachycardia. The most common reason for discontinuing ivabradine was lack of efficacy (n = 6). Five patients reported side-effects resulting in two discontinuing treatment.
This retrospective case series indicates that 60% of patients treated with ivabradine report a symptomatic improvement. A randomized controlled trial accessing the efficacy of ivabradine in POTS is indicated, particularly in patients resistant to, or intolerant of, conventional therapy.
体位性心动过速综合征(POTS)与直立时心动过速有关。患者常报告心悸、晕厥前状态和疲劳。常规治疗的有效率低于 60%。病例报告表明伊伐布雷定(一种选择性窦房结阻滞剂,对血压没有影响)可能缓解与 POTS 相关的症状。这是一项回顾性病例系列研究。
从药房数据库中确定了开处方伊伐布雷定的体位性心动过速综合征患者。查阅病历,并让参与者完成症状评估工具。确定了 22 名患者。有 20 名患者的数据可用。8 名患者报告心动过速和疲劳减轻,4 名患者仅报告心动过速减轻。停止使用伊伐布雷定最常见的原因是缺乏疗效(n=6)。有 5 名患者报告出现副作用,导致 2 名患者停止治疗。
这项回顾性病例系列研究表明,60%接受伊伐布雷定治疗的患者报告症状改善。需要进行一项评估伊伐布雷定在 POTS 中的疗效的随机对照试验,特别是在对常规治疗有抵抗或不耐受的患者中。